Additionally, Eisai has assigned the patent right for its metabolic enzyme inhibitor E7727 to Otsuka.
As part of the deal, Eisai will transfer to Otsuka its rights to exclusively develop and market Dacogen in the US, Canada and Japan, as well as the licensing rights for this product in all other countries excluding Mexico, in which Eisai will retain its rights for Dacogen.
Dacogen is an intravenous formulation of decitabine used in the treatment of myelodysplastic syndrome (MDS), in which ineffective or abnormal production of the myeloid class of blood cells occurs, and in the treatment of acute myeloid leukemia (AML).
The drug was originally developed by Otsuka’s US subsidiary Astex Pharmaceuticals and in 2008, Eisai obtained an exclusive license for its development, manufacture and marketing worldwide.
According to Eisai, the deal will lead to maximization of Dacogen’s product and patient value.